Feedback
Settings

Settings

Goto Application

126,928 results
Offices all Languages Stemming false Single Family Member true

Save query

A private query is only visible to you when you are logged-in and can not be used in RSS feeds

Query Tree

Refine Options

Offices
All
Specify the language of your search keywords
Stemming reduces inflected words to their stem or root form.
For example the words fishing, fished,fish, and fisher are reduced to the root word,fish,
so a search for fisher returns all the different variations
Returns only one member of a family of patents

Full Query

IC:A61K45/00

Side-by-side view shortcuts

General
Go to Search input
CTRL + SHIFT +
Go to Results (selected record)
CTRL + SHIFT +
Go to Detail (selected tab)
CTRL + SHIFT +
Go to Next page
CTRL +
Go to Previous page
CTRL +
Results (First, do 'Go to Results')
Go to Next record / image
/
Go to Previous record / image
/
Scroll Up
Page Up
Scroll Down
Page Down
Scroll to Top
CTRL + Home
Scroll to Bottom
CTRL + End
Detail (First, do 'Go to Detail')
Go to Next tab
Go to Previous tab

Analysis

1 / 12,693
1.WO/2021/010937METHODS AND COMPOSITIONS FOR THE TREATMENT OF SICKLE CELL DISEASES AND THALASSEMIA
WO - 21.01.2021
Int.Class A61K 31/365
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
31Medicinal preparations containing organic active ingredients
33Heterocyclic compounds
335having oxygen as the only ring hetero atom, e.g. fungichromin
365Lactones
 Appl.No PCT/US2019/000033 Applicant EMMAUS MEDICAL, INC. Inventor NIIHARA, Yutaka
The present invention is generally directed to methods and compositions for the treatment of sickle cell diseases and thalassemia. It is more particularly directed to compositions containing L-glutamine, an L-glutamine salt or an L-glutamine derivative and at least one other active ingredient and methods using such compositions. In one aspect, the present invention is directed to a composition for treating sickle cell disease or β-thalassemia. The composition comprises: at least one gram of L-glutamine, an L-glutamine salt or an L-glutamine derivative; and, at least one gram of one type of fiber.
2.WO/2021/008161DRUG FOR ALLEVIATING PSEUDOMONAS KERATITIS
WO - 21.01.2021
Int.Class A61K 45/00
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
45Medicinal preparations containing active ingredients not provided for in groups A61K31/-A61K41/132
 Appl.No PCT/CN2020/080812 Applicant SHANDONG EYE INSTITUTE Inventor ZHOU, Qingjun
A drug for alleviating pseudomonas keratitis, characterized by comprising a β2-adrenergic receptor inhibitor having a structure represented by formula (I).
3.WO/2021/009142COMPOSITION COMPRISING AT LEAST ONE OXAZOLINE FOR INHIBITING THE GROWTH OF MALASSEZIA YEASTS INVOLVED IN CRADLE CAP, IN PARTICULAR
WO - 21.01.2021
Int.Class A61K 9/00
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
9Medicinal preparations characterised by special physical form
 Appl.No PCT/EP2020/069799 Applicant LABORATOIRES EXPANSCIENCE Inventor BRÉDIF, Stéphanie
The present invention relates to a composition comprising at least one oxazoline, such as OΧ100, which inhibits the growth of Malassezia yeast and/or prevents and/or treats ailments caused by Malassezia yeast, seborrhoeic dermatitis, cradle cap, Malassezia folliculitis, dandruff, pityriasis versicolor or pityriasis capitis. The present invention also relates to a composition comprising at least one oxazoline such as OΧ100, at least one compound such as malic acid diester and an oleodistillate of vegetable oil and/or arabinogalactan, and to its use in preventing and/or treating, in particular, ailments caused by Malassezia yeast, seborrhoeic dermatitis, cradle cap, Malassezia folliculitis, dandruff, pityriasis versicolor or pityriasis capitis.
4.WO/2021/011887CLOSTRIDIA CONSORTIA COMPOSITIONS AND METHODS OF TREATING OBESITY, METABOLIC SYNDROME AND IRRITABLE BOWEL DISEASE
WO - 21.01.2021
Int.Class A61K 9/00
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
9Medicinal preparations characterised by special physical form
 Appl.No PCT/US2020/042578 Applicant UNIVERSITY OF UTAH RESEARCH FOUNDATION Inventor ROUND, June, L.
Disclosed herein, are compositions comprising a consortium of Clostridia, and methods of treating obesity, metabolic syndrome, irritable bowel disease, as well as reducing weight gain and inhibiting lipid absorption in the small intestine by administering the compositions to a subject.
5.WO/2021/011466USE OF NANOPARTICLES FOR TREATING RESPIRATORY INFECTIONS ASSOCIATED WITH CYSTIC FIBROSIS
WO - 21.01.2021
Int.Class A61K 31/712
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
31Medicinal preparations containing organic active ingredients
70Carbohydrates; Sugars; Derivatives thereof
7088Compounds having three or more nucleosides or nucleotides
712Nucleic acids or oligonucleotides having modified sugars, i.e. other than ribose or 2'-deoxyribose
 Appl.No PCT/US2020/041796 Applicant ATTOSTAT, INC. Inventor NIEDERMEYER, William
This disclosure relates to metal nanoparticle compositions and methods for treating respiratory infections associated with cystic fibrosis. An amount of nonionic, ground state metal nanoparticles are administered to a patient via inhalation. The metal nanoparticles have properties that enable effective transport through the viscous mucus layer to the epithelia and surrounding tissues, killing or deactivating infecting microbes at the targeted respiratory tissue and throughout the overlying mucus layer.
6.WO/2021/011660METHODS AND COMPOSITIONS FOR DETECTION AND TREATMENT OF LUNG CANCER
WO - 21.01.2021
Int.Class A61K 39/395
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
39Medicinal preparations containing antigens or antibodies
395Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
 Appl.No PCT/US2020/042146 Applicant ONCOCYTE CORPORATION Inventor HESTERBERG, Lyndal, K.
Disclosed herein are methods for detecting whether a subject is at risk of lung cancer based on a blood-based multivariate gene expression classifier. Methods for determining whether to obtain a biopsy in a subject based on a blood-based multivariate gene expression classifier are also disclosed. Further disclosed are methods for treating lung cancer based on a blood-based multivariate gene expression classifier are disclosed. Kits for detecting the expression levels of biomarkers for determining whether a subject is at risk of lung cancer are also disclosed.
7.WO/2021/009664METHODS FOR TREATING MEIBOMIAN GLAND DYSFUNCTION WITH LIVER X RECEPTOR AGONISTS
WO - 21.01.2021
Int.Class A61K 31/405
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
31Medicinal preparations containing organic active ingredients
33Heterocyclic compounds
395having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
40having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
403condensed with carbocyclic rings, e.g. carbazole
404Indoles, e.g. pindolol
405Indole-alkanecarboxylic acids; Derivatives thereof, e.g. tryptophan, indomethacin
 Appl.No PCT/IB2020/056584 Applicant NOVARTIS AG Inventor ADAMS, Christopher M.
The present invention provides methods for treating treating meibomian gland dysfunction using liver X receptor (LXR) agonists.
8.WO/2021/011404THERAPEUTIC PROTEIN FORMULATIONS COMPRISING ANTIBODIES AND USES THEREOF
WO - 21.01.2021
Int.Class A61K 39/00
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
39Medicinal preparations containing antigens or antibodies
 Appl.No PCT/US2020/041687 Applicant CONTRAFECT CORPORATION Inventor THARIATH, Abraham
The present disclosure is directed to an aqueous therapeutic protein formulation including: (i) one or more therapeutic proteins, wherein the one or more therapeutic proteins include one or more anti-influenza antibodies or antigen-binding fragments thereof in an amount ranging from 30 to 150 mg/mL; (ii) histidine buffer, (iii) NaCl, and (iv) an aqueous carrier, wherein a pH of the aqueous therapeutic formulation ranges from 5.5-8.0, and wherein the formulation is formulated for respiratory tract delivery and produces particles including the one or more therapeutic proteins upon aerosolization. Methods of generating an aerosol and treating influenza are also provided.
9.WO/2021/010698CANCER CELL-TARGETED DRUG DELIVERY CARRIER AND COMPOSITION FOR PROMOTING PHOTO-THERMAL TREATMENT EFFECTS, BOTH OF WHICH CONTAIN M1 MACROPHAGES AS ACTIVE INGREDIENT
WO - 21.01.2021
Int.Class A61K 41/00
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
41Medicinal preparations obtained by treating materials with wave energy or particle radiation
 Appl.No PCT/KR2020/009173 Applicant KOREA UNIVERSITY RESEARCH AND BUSINESS FOUNDATION Inventor BAEK, Seung Kuk
The present invention relates to a cancer cell-targeted drug delivery carrier, a composition for promoting photo-thermal treatment effects, and the like, which contain M1 macrophages as an active ingredient. The drug delivery carrier of the present invention uses the M1 macrophage mobility to tumor cells and the M1 macrophage penetrability into tumors, and can deliver drugs specifically to tumor and cancer tissues only, and, when performing photo-thermal treatment by loading M1 macrophages with a photosensitive material, can significantly increase the effects, and thus is expected to be effectively used for promoting cancer treatment effects.
10.WO/2021/007800ANTI-INFECTION EFFECTS OF HNRNPA2B1 AND USE THEREOF
WO - 21.01.2021
Int.Class A61K 38/17
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
38Medicinal preparations containing peptides
16Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
17from animals; from humans
 Appl.No PCT/CN2019/096303 Applicant INSTITUTE OF BASIC MEDICAL SCIENCES, CHINESE ACADEMY OF MEDICAL SCIENCES Inventor CAO, Xuetao
Provided are anti-infection effects of a heterogeneous nuclear ribonucleoprotein A2B1 (hnRNPA2B1) and use thereof. In particular, provided are use of hnRNPA2B1, a nucleic acid molecule encoding the protein, and an accelerator thereof or an inhibitor thereof in the preparation of a product for preventing and/or treating infectious diseases and/or diseases and/or conditions associated with infection, and a corresponding pharmaceutical composition or kit thereof. The present invention can be used for preventing and inhibiting infections (such as virus infections) and diagnosing and treating autoimmune diseases related to self-nucleic acids, and has wide application prospects.
# -